Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.
Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.|BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Folefac
F
Aminkeng
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Colin J D
CJD
Ross
BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.|Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Shahrad R
SR
Rassekh
Department of Pediatrics, University of Western Ontario, London, Ontario, Canada.
Michael J
MJ
Rieder
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Amit P
0000-0003-3336-9288
AP
Bhavsar
BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Shubhayan
S
Sanatani
Department of Pediatrics, Division of Cardiology, Stanford University, Stanford, California, USA.
Daniel
D
Bernstein
Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.|BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.|Teva Pharmaceutical Industries, Petach Tikva, Israel.
Michael R
MR
Hayden
University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern, Switzerland.
Ursula
U
Amstutz
BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.|Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Bruce C
BC
Carleton
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D066126:Cardiotoxicity; D006801:Humans; D009369:Neoplasms; D000071185:Pharmacogenomic Testing
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic
anthracycline; anthracycline-induced cardiotoxicity; cancer; chemotherapy; clinical practice guidelines; congestive heart failure; pharmacogenomic screening